CureVac Sues Moderna in mRNA Vaccine Patent Showdown

A New Front in the mRNA Patent Wars

German biotech company CureVac has launched a fresh patent infringement lawsuit against Moderna in Delaware federal court, claiming that Moderna's blockbuster COVID-19 vaccine Spikevax infringes eight of its US patents covering core mRNA technology. The suit specifically targets methods for stabilising the fragile mRNA molecules that sit at the heart of modern vaccines, and CureVac is seeking royalties on Spikevax sales worldwide.

Moderna has confirmed it is aware of the lawsuit and intends to defend itself vigorously. Representatives for CureVac and its new parent company BioNTech have so far declined to comment publicly. The timing is notable: BioNTech, which partners with Pfizer on the rival Comirnaty vaccine, completed a $1.25 billion all-stock acquisition of CureVac in late 2025, instantly inheriting one of the most valuable mRNA patent portfolios in the industry.

Moderna's Mounting Legal Bills

The new case adds to a snowballing series of intellectual property battles for Moderna. In March, the company agreed to pay up to $2.25 billion to settle a dispute with Arbutus Biopharma and Genevant Sciences over the lipid nanoparticle delivery technology used in Spikevax, including a $950 million upfront payment made just days before a Delaware jury trial was due to begin. BioNTech also filed its own US patent suit against Moderna in February, this time targeting the next-generation mNEXSPIKE jab.

The broader picture is one of an industry still fighting over the foundations of a technology that generated tens of billions of dollars during the pandemic. GlaxoSmithKline, Bayer, and Alnylam Pharmaceuticals have all filed similar lawsuits, while Moderna's own 2022 case against Pfizer and BioNTech grinds on.

A Resolved Past, A Contested Future

CureVac itself settled an earlier patent fight with Pfizer and BioNTech in August 2025, receiving $740 million plus single-digit royalties on US COVID-19 vaccine sales. With CureVac now operating as a BioNTech subsidiary, the legal pressure on Moderna intensifies. The outcome could reshape the economics of mRNA platforms as they expand into cancer vaccines, bird flu shots, and even veterinary medicine, where regulators recently approved the first RNA-based animal vaccine in the EU.